IP Verse

Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement - EP3167888

The patent EP3167888 was granted to Alexion Pharmaceuticals on May 1, 2024. The application was originally filed on Mar 15, 2007 under application number EP16195355A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3167888

ALEXION PHARMACEUTICALS
Application Number
EP16195355A
Filing Date
Mar 15, 2007
Status
Granted And Under Opposition
Mar 29, 2024
Publication Date
May 1, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SALUTE HC ILAC PAZARLAMAJan 31, 2025GRUNECKER PATENTADMISSIBLE
AMGEN TECHNOLOGY IRELAND UNLIMITEDOct 28, 2024DORRIESADMISSIBLE
AMGEN TECHNOLOGY IRELAND UNLIMITEDOct 28, 2024DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE
SAMSUNG BIOEPISMay 2, 2024SIMMONS & SIMMONS MUNICHADMISSIBLE

Patent Citations (58) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0120694
DESCRIPTIONEP0194276
DESCRIPTIONEP0239400
DESCRIPTIONEP0404097
DESCRIPTIONUS2003129187
DESCRIPTIONUS2003202972
DESCRIPTIONUS2004091490
DESCRIPTIONUS2005158316
DESCRIPTIONUS2005226870
DESCRIPTIONUS2005238646
DESCRIPTIONUS4816397
DESCRIPTIONUS4816567
DESCRIPTIONUS4946778
DESCRIPTIONUS5225539
DESCRIPTIONUS5260203
DESCRIPTIONUS5565332
DESCRIPTIONUS5660825
DESCRIPTIONUS5693762
DESCRIPTIONUS5789208
DESCRIPTIONUS6057131
DESCRIPTIONUS6100443
DESCRIPTIONUS6103889
DESCRIPTIONUS6180370
DESCRIPTIONUS6331415
DESCRIPTIONUS6335163
DESCRIPTIONUS6355245
DESCRIPTIONUS6407213
DESCRIPTIONUS6534058
DESCRIPTIONUS6548640
DESCRIPTIONWO03106644
DESCRIPTIONWO2004009618
DESCRIPTIONWO2004066957
DESCRIPTIONWO2004091658
DESCRIPTIONWO2005074607
DESCRIPTIONWO8601533
DESCRIPTIONWO9210205
DESCRIPTIONWO9311161
DESCRIPTIONWO9520401
EXAMINATIONUS2005271660
EXAMINATIONUS6355245
EXAMINATIONWO2005074607
OPPOSITIONUS2003232972
OPPOSITIONUS2005191298
OPPOSITIONUS6355245
OPPOSITIONWO2004050017
OPPOSITIONWO2004108158
OPPOSITIONWO2005007809
OPPOSITIONWO2005074607
OPPOSITIONWO9711971
OTHEREP1720571
OTHEREP1755674
OTHEREP1988882
OTHEREP2061810
OTHEREP2359834
OTHEREP2380907
OTHERUS2005271660
OTHERWO2007092772
SEARCHUS2005191298

Non-Patent Literature (NPL) Citations (128) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AARONSON NK; AHMEDZAI S; BERGMAN B ET AL., "The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.", J NATL CANCER INST, (1993), vol. 85, pages 365 - 76
DESCRIPTION- ALTSCHUL ET AL., J. MOL. BIOL., (1997), vol. 215, pages 403 - 410
DESCRIPTION- BESSLER M; MASON PJ; HILLMEN P ET AL., "Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene", EMBO J, (1994), vol. 13, pages 110 - 7
DESCRIPTION- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
DESCRIPTION- C. A. JANEWAY ET AL., Immunobiology, 5th ed., GARLAND PUBLISHING, (2001), page 147
DESCRIPTION- CELLA D; ETON DT; LAI JS; PETERMAN AH; MERKEL DE., "Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.", J PAIN SYMPTOM MANAGE, (2002), vol. 24, pages 547 - 61
DESCRIPTION- CELLA D., Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, CENTER ON OUTCOMES RESEARCH AND EDUCATION, (1997), vol. 4
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
DESCRIPTION- CRUM ET AL., JAMA, (1993), vol. 269, no. 18, page 2386
DESCRIPTION- CUMMINGS, JAMA, (1993), vol. 269, no. 18, page 2420
DESCRIPTION- FOLSTEIN ET AL., J. PSYCHIAT. RES., (1975), vol. 12, page 189
DESCRIPTION- FREI ET AL., MOL. CELL. PROBES, (1987), vol. 1, pages 141 - 149
DESCRIPTION- GRANT ET AL., CHEST, vol. 116, (1999), page 1208, URL: www.qolid.org
DESCRIPTION- HILL A; ROTHER RP; HILLMEN P., "Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.", HAEMATOLOGICA, (2005), vol. 90, page ECR40
DESCRIPTION- HILL A; WANG X; SAPSFORD RJ ET AL., "Nitric oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.", BLOOD, (2005), vol. 106, no. 11
DESCRIPTION- HILL A; WANG X; SAPSFORD RJ ET AL., "Nitric oxide Consumption and Pulmonary Hypertension in Patients, with Paroxysmal Nocturnal Hemoglobinuria.", BLOOD, (2005), vol. 106, page A1046
DESCRIPTION- HILLRRIEN P; HALL C; MARSH JC ET AL., "Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.", N ENGL J MED, (2004), vol. 350, pages 552 - 9
DESCRIPTION- HOLGUIN MH; FREDRICK LR; BEMSHAW ' NJ; WILCOX LA; PARKER CJ., "Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.", J CLIN INVEST, (1989), vol. 84, pages 7 - 17
DESCRIPTION- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
DESCRIPTION- JASINSKI M; PANTAZOPOULOS P; ROTHER RP ET AL., "A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins.", BLOOD, (2004), vol. 103, pages 2827 - 34
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 5
DESCRIPTION- KABAT AND MAYER, Experimental Immunochemistry, 2nd ed., (1961), pages 135 - 240
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, pages 495 - 497
DESCRIPTION- KOKMEN ET AL., MAYO CLIN. PROC., (1987), vol. 62, page 281
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
DESCRIPTION- MOLLNES ET AL., SCAND. J. IMMUNOL, (1988), vol. 28, pages 307 - 312
DESCRIPTION- MONTZ ET AL., CELLULAR IMMUNOL, (1990), vol. 127, pages 337 - 351
DESCRIPTION- MOTOYAMA N; OKADA N; YAMASHINA M; OKADA H., "Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene.", EUR J IMMUNOL, (1992), vol. 22, pages 2669 - 73
DESCRIPTION- NEWMAN ET AL., BIOTECHNOLOGY, (1992), vol. 10, pages 1455 - 1460
DESCRIPTION- PARKER C; OMINE M; RICHARDS S ET AL., "Diagnosis and management of paroxysmal nocturnal hemoglobinuria.", BLOOD, (2005), vol. 106, pages 3699 - 709
DESCRIPTION- PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
DESCRIPTION- ROLLINS SA; SIMS PJ., "The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.", J IMMUNOL, (1990), vol. 144, pages 3478 - 83
DESCRIPTION- ROSSE WF., "Paroxysmal nocturnal hemoglobinuria.", HOFFINAN. NEW YORK: CHURCHILL LIVINGSTONE, (2000), pages 331 - 342
DESCRIPTION- ROTHER RP; BELL L; HILLMEN P; GLADWIN MT., "The clinical sequelae of intravascular hemolysis and extravascular plasma hemoglobin: a novel mechanism of human disease", JAMA, (2005), vol. 293, pages 1653 - 62
DESCRIPTION- SIMS PJ; ROLLINS SA; WIEDMER T., "Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex", J BIOL CHEM, (1989), vol. 264, pages 19228 - 35
DESCRIPTION- TAKEDA J; MIYATA T; KAWAGOE K ET AL., "Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.", CELL, (1993), vol. 73, pages 703 - 11
DESCRIPTION- TAMBURINI, ANN. ONCOL., (2001), vol. 12, no. 3, page S7
DESCRIPTION- TANG-WAI ET AL., ARCH. NEUROL., (2003), vol. 60, page 1777
DESCRIPTION- "The United States Pharmacopeial Convention", PHARMACOPEIAL FORUM, (2000), vol. 26, no. 1, page 223
DESCRIPTION- THOMAS TC; ROLLINS SA; ROTHER RP ET AL., "Inhibition of complement activity by humanized antibody that binds C5 and single-chain Fv.", MOL IMMUNOL, (1996), vol. 33, pages 1389 - 401
DESCRIPTION- TOMBAUGH ET AL., J. AM. GERIATR. SOC., (1992), vol. 40, page 922
DESCRIPTION- WARD; ZVAIFLER, J CLIN INVEST., (197103), vol. 50, no. 3, pages 606 - 16
DESCRIPTION- WEBSTER ET AL., HEALTH AND QUALITY OF LIFE OUTCOMES., vol. 1, (2003), page 79, URL: www.hqlo.com/content/I/I/79
DESCRIPTION- WEINSTEIN ET AL., N ENGL J MED, (1977), vol. 296, pages 716 - 721
DESCRIPTION- WEINSTEIN MC; STASON WB, N ENGL J MED, (1977), vol. 296, pages 716 - 721
DESCRIPTION- WIEDMER T; HALL SE; ORTEL TL; KANE WH; ROSSE WF; SIMS PJ., "Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.", BLOOD, (1993), vol. 82, pages 1192 - 6
DESCRIPTION- WILKINS ET AL., AM J PUBLIC HEALTH, (1983), vol. 73, pages 1073 - 1080
DESCRIPTION- WILKINS, R.; ADAMS, OB., AM J PUBLIC HEALTH, (1983), vol. 73, pages 1073 - 1080
DESCRIPTION- WURZNER ET AL., COMPLEMENT INFLAMM., (1991), vol. 8, pages 328 - 340
DESCRIPTION- YAMASHINA M; UEDA E; KINOSHITA T ET AL., "Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria.", N ENGL J MED, (1990), vol. 323, pages 1184 - 9
DESCRIPTION- YELLEN SB; CELLA DF; WEBSTER K; BLENDOWSKI C; KAPLAN E., "Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.", J PAIN SYMPTOM MANAGE, (1997), vol. 13, pages 63 - 74
DESCRIPTION- ZAPATA ET AL., PROTEIN ENG, (1995), vol. 8, pages 1057 - 1062
EXAMINATION- THOMAS T C ET AL, "Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (19960101), vol. 33, no. 17-18, doi:10.1016/S0161-5890(96)00078-8, ISSN 0161-5890, pages 1389 - 1401, XP002262113
OPPOSITION- Allen Deborah, "PROPERTIES AND BIOLOGICAL ACTIVITIES* OF CLASSES AND SUBCLASSES OF HUMAN SERUM IMMUNOGLOBULINS", Immunology, Third Edition, (19970101), page 125, XP093260238
OPPOSITION- Anonymous, "ALEXION Completes Enrollment in Phase II Membranous Nephritis Clinical Trial with 5G1.1", Press release, (20020220), pages 1 - 2, XP093260315
OPPOSITION- Anonymous, "GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS ", Emea, COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP), (20071201), pages 1 - 18, XP093260233
OPPOSITION- Anonymous, "GUIDELINES ON THE USE OF INTERNATIONAL NONPROPRIETARY NAMES (INNs) FOR PHARMACEUTICAL SUBSTANCES", HO/PHARM S/MON 1570:, World Health Organization, (19970101), pages 1 - 40, XP093260540
OPPOSITION- D01: The Final Order of the Hamburg Local Division of June 26, 2024 in case UPC_CFI_124/2024, ORD_38032/2024
OPPOSITION- D02: Overview over claims sought by Alexion and discussed in TBA decisions
OPPOSITION- D03: INN Publication for eculizumab
OPPOSITION- D04: Decision of the CoA of the UPC dated December 20, 2024
OPPOSITION- D05: Proprietor’s submissions in relation to EP 1 720 571
OPPOSITION- D06: Proprietor’s submission of 2 August 2011 in relation to US 11/127,438
OPPOSITION- D07: Proprietor’s Submission at the EPO of 15 November 2012
OPPOSITION- D08: Declaration of Prof. Kontermann
OPPOSITION- D09: CV of Professor Roland Kontermann
OPPOSITION- D129 - UPC Final Order
OPPOSITION- D130 - Decision UK court
OPPOSITION- D131 - Preliminary Opinion BoA T1087_19
OPPOSITION- D23: Sequence alignment with D11 and D12
OPPOSITION- D26: Grounds for the decision to refuse the patent application, dated February 11, 2020
OPPOSITION- D27: T 1515/20
OPPOSITION- D28: Final Order UPC LD Hamburg (UPC_CFI_123/2004)
OPPOSITION- D29: Final Order UPC Court of Appeal (UPC_CFI_123/2004)
OPPOSITION- D30: Final Order UPC Court of Appeal (UPC_CFI_124/2004)
OPPOSITION- D31: Case Law of the BoA, 10th edition, p. 122 - 124; I.C.4.2
OPPOSITION- D32: T 0153/85
OPPOSITION- D33: CAS Database Registry for Eculizumab (RN 219685-50-4, 14 February 1999)
OPPOSITION- D47: Application US 08/487283
OPPOSITION- D50: EP 11 001 632.6 - Decision revoking the European patent
OPPOSITION- D51: EP 16 172 335.8 - Decision to refuse a European patent application (28.01.2020)
OPPOSITION- D52: EP 16 172 335.8 - Decision to refuse a European patent application (11.02.2020)
OPPOSITION- D57: Sequence listing for EP - Counterpart of Rother WO
OPPOSITION- D58: EP 11 001 632.6_Applicant’s submission of 15.11.2012
OPPOSITION- D60: Affidavit of F. Bertelli (30.04.2024)
OPPOSITION- D61: F. Bertelli’s CV
OPPOSITION- D62: Sequence overview_F. Bertelli
OPPOSITION- D64: Affidavit of F. Bertelli (14.06.2024)
OPPOSITION- D66: Alexion Press Release
OPPOSITION- D70: EP 11 001 632.6_Proprietor’s statement of ground of appeal
OPPOSITION- D71: EP 2 359 834_Second declaration of Dino Miano (14.01.2019)
OPPOSITION- D72: Prof. Dr. Arne Skerra_Witness declaration
OPPOSITION- Frank Michael M, Miletic Vojislav D, Jiang Haixiang, "Immunoglobulin in the Control of Complement Action", Immunologic Research, (20000101), vol. 22, no. 2, pages 137 - 146, XP093260241
OPPOSITION- Hill Anita, "Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.", Clinical Advances in Hematology & Oncology, Millenium medical pub , New York , NY, US, US , (20051101), vol. 3, no. 11, ISSN 1543-0790, pages 849 - 850, XP001538426
OPPOSITION- Hillmen P C et al, "Eculizumab, a C5 complement blocking antibody, is the first therapy to reduce transfusion requirements in patients with paroxysmal nocturnal haemoglobinuria (PNH)", British Journal of Haematolog, Blackwell Publishing, (20030101), vol. 121, no. Suppl. 1, pages 87 - 95, XP093260326
OPPOSITION- Kaplan Mariana, "Eculizumab (Alexion).", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, US , (20020701), vol. 3, no. 7, ISSN 1472-4472, pages 1017 - 1023, XP009506295
OPPOSITION- Nezu Jun-Ichi et al, "Identification of CDCP1 as a novel molecular target of anti-cancer therapeutic antibody targeting prostate cancer", American Association for Cancer Research. Proceedings of the Annual Meeting, American Association for Cancer Research, US, US , (20070401), vol. 48, ISSN 0197-016X, page 153, XP008115766
OPPOSITION- Russo Noonan, "Alexion Pharmaceuticals Reports Positive Phase III Results for Eculizumab From Pivotal TRIUMPH Efficacy Trial in Paroxysmal Nocturnal Hemoglobinuria Patients", Press Release, (20060126), pages 1 - 4, XP093260307
OPPOSITION- Pierangeli Silvia S. et al, "Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia", Arthritis & Rheumatism, Wiley InterScience, US, US , (20050701), vol. 52, no. 7, doi:10.1002/art.21157, ISSN 0004-3591, pages 2120 - 2124, XP093260537
OPPOSITION- WANG W; SINGH S; ZENG D L; KING K; NEMA S, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", Journal of pharmaceutical sciences, Elsevier Inc, Hoboken, Hoboken, (20070101), vol. 96, no. 1, doi:10.1002/jps.20727, ISSN 0022-3549, pages 1 - 26, XP009084505
OPPOSITION- Feinstein, A. ; Richardson, N. ; Taussig, M.I., "Immunoglobulin flexibility in complement activation", Immunology today, ELSEVIER PUBLICATIONS, CAMBRIDGE., GB, GB , (19860601), vol. 7, no. 6, doi:10.1016/0167-5699(86)90168-4, ISSN 0167-5699, pages 169 - 174, XP023943155
OPPOSITION- Presta, L.G., "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20060807), vol. 58, no. 5-6, doi:10.1016/j.addr.2006.01.026, ISSN 0169-409X, pages 640 - 656, XP005611419
OPPOSITION- Daugherty, A.L. Mrsny, R.J., "Formulation and delivery issues for monoclonal antibody therapeutics", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20060807), vol. 58, no. 5-6, doi:10.1016/j.addr.2006.03.011, ISSN 0169-409X, pages 686 - 706, XP005611422
OPPOSITION- Wang, W., "Protein aggregation and its inhibition in biopharmaceutics", International Journal of Pharmaceutics, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (20050131), vol. 289, no. 1-2, doi:10.1016/j.ijpharm.2004.11.014, ISSN 0378-5173, pages 1 - 30, XP004706998
OPPOSITION- Thomas Thomas C. et al, "Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv", Molecular Immunology, PERGAMON, GB, GB , (19961201), vol. 33, no. 17-18, doi:10.1016/S0161-5890(96)00078-8, ISSN 0161-5890, pages 1389 - 1401, XP093260245
OPPOSITION- MUELLER J.P. ET AL, "Humanized porcine VCAM-specific monoclonal antibidies with chimeric igG2/G4 constant regions block human leukocyte binding to porcine endothelial cells.", Molecular Immunology, PERGAMON, GB, GB , (19970101), vol. 34, no. 6, doi:10.1016/S0161-5890(97)00042-4, ISSN 0161-5890, pages 441 - 452, XP002988985
OPPOSITION- BREKKE O H, SANDLIE I, "THERAPEUTIC ANTIBODIES FOR HUMAN DISEASES AT THE DAWN OF THE TWENTY-FIRST CENTURY.", Nature Reviews. Drug Discovery, Nature Publishing Group, GB, GB , (20030101), vol. 2, doi:10.1038/nrd984, ISSN 1474-1784, pages 52 - 62, XP003009494
OPPOSITION- Marina Noris, Federica Mescia, Giuseppe Remuzzi, "STEC-HUS, atypical HUS and TTP are all diseases of complement activation", Nature reviews. Nephrology, Nature Publishing Group, GB, GB , vol. 8, no. 11, doi:10.1038/nrneph.2012.195, ISSN 1759-5061, pages 622 - 633, XP055259427
OPPOSITION- HILLMEN P, ET AL., "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20040205), vol. 350, no. 06, doi:10.1056/NEJMoa031688, ISSN 1533-4406, pages 552 - 559, XP009057948
OPPOSITION- Bindon C I, Hale G, Brüggemann M, Waldmann H, "Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.", Journal of Experimental Medicine, Rockefeller University Press, US, US , (19880701), vol. 168, no. 1, doi:10.1084/jem.168.1.127, ISSN 0022-1007, pages 127 - 142, XP093138374
OPPOSITION- CANFIELD S M, MORRISON S L, "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION", Journal of Experimental Medicine, Rockefeller University Press, US, US , (19910601), vol. 173, no. 06, doi:10.1084/jem.173.6.1483, ISSN 0022-1007, pages 1483 - 1491, XP001181027
OPPOSITION- Hamilton Rg, Abmli D, Mohan Chandra, "<mark>Human IgG subclass</mark> measurements in the clinical laboratory", Clinical Chemistry, Oxford University Press, US, US , (19871001), vol. 33, no. 10, doi:10.1093/clinchem/33.10.1707, ISSN 0009-9147, pages 1707 - 1725, XP093260502
OPPOSITION- Chen H, Kim J, Kendall D A, "Competition between functional signal peptides demonstrates variation in affinity for the secretion pathway", Journal of Bacteriology, American Society for Microbiology, US, US , (19961201), vol. 178, no. 23, doi:10.1128/jb.178.23.6658-6664.1996, ISSN 0021-9193, pages 6658 - 6664, XP093260223
OPPOSITION- RAVETCH J V, BOLLAND S, "IGG FC RECEPTORS", Annual Review of Immunology, Annual Reviews Inc., (20010101), vol. 19, doi:10.1146/annurev.immunol.19.1.275, ISSN 0732-0582, pages 275 - 290, XP008008612
OPPOSITION- ROSSE WENDELL F , HILLMEN P, SCHREIBER A D, "Immune-mediated hemolytic anemia.", American society of hematology, American society of hematology, Washington, DC, US, US , (20040101), doi:10.1182/asheducation-2004.1.48, ISSN 1520-4391, pages 48 - 62, XP002497825
OPPOSITION- TACKEN PAUL J ET AL, "Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20050815), vol. 106, no. 4, doi:10.1182/blood-2005-01-0318, ISSN 0006-4971, pages 1278 - 1285, XP002449006
OPPOSITION- Takahiko Horiuchi, Tsukamoto Hiroshi, "Complement-targeted therapy: development of C5- and C5a-targeted inhibition", Inflammation and Regeneration, (20161201), vol. 36, no. 1, doi:10.1186/s41232-016-0013-6, pages 1 - 5, XP055644542
OPPOSITION- CROMWELL MARY E M , HILARIO E, JACOBSON F, "Protein aggregation and bioprocessing.", AAPS JOURNAL, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, US, US , (20060901), vol. 8, no. 3, doi:10.1208/aapsj080366, ISSN 1550-7416, pages E572 - E579, XP002557046
OPPOSITION- Harding J, "Eculizumab", Drugs of the Future, Prous Science, ES, ES , (20040701), vol. 29, no. 7, doi:10.1358/dof.2004.029.07.819330, ISSN 0377-8282, pages 673 - 676, XP008113000
OPPOSITION- Anonymous, "Eculizumab: 5G1.1, h5G1.1, long-acting anti-C5 monoclonal antibody 5G1-1, long-acting anti-C5 monoclonal antibody 5G1.1", Drugs in R&D, Adis International Ltd , nzl, (20070101), vol. 8, no. 1, doi:10.2165/00126839-200708010-00006, ISSN 1174-5886, pages 61 - 68, XP009161624
OPPOSITION- Gogesch Patricia et al, "The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies", International Journal of Molecular Sciences, vol. 22, no. 16, doi:10.3390/ijms22168947, page 8947, XP093069323
OPPOSITION- Paul R Hinton, Joanna M Xoing, Mary G Johlfs, et al, "An engineered human IgG1 antibody with longer serum half-life.", Journal of Immunology, Williams & Wilkins, (20060101), vol. 176, no. 1, doi:10.4049/jimmunol.176.1.346, ISSN 0022-1767, pages 346 - 356, XP002484005
OTHER- MUELLER et al., "Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells", Mol Immunol, (19970000), vol. 34, no. 6, pages 441 - 452, XP055166865
SEARCH- HILL ANITA, "Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, MILLENNIUM MEDICAL PUB., NEW YORK, NY, US, (20051101), vol. 3, no. 11, ISSN 1543-0790, pages 849 - 850, XP001538426 [X] 1-3 * the whole document *
SEARCH- HILLMEN P ET AL, "Eculizumab, a C5 complement blocking antibody, is the first therapy to reduce transfusion requirements in patients with paroxysmal nocturnal haemoglobinuria (PNH)", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, (20030501), vol. 121, no. Suppl.1, ISSN 0007-1048, page 87, XP009144758 [X] 1-3 * the whole document *
SEARCH- REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (19990214), Database accession no. 219685-50-4, URL: STN, XP002767828 [X] 1-2 * abstract *
SEARCH- HILLMEN P ET AL, "EFFECT OF ECULIZUMAB ON HEMOLYSIS AND TRANSFUSION REQUIREMENTS IN PATIENTS WITH PAROXYSMAL NOCTRURNAL HEMAGLOBINURIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20040205), vol. 350, no. 6, doi:10.1056/NEJMOA031688, ISSN 1533-4406, pages 552 - 559, XP009057948 [DX] 1-3 * abstract *
SEARCH- HARDING J, "Eculizumab", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, (20040701), vol. 29, no. 7, doi:10.1358/DOF.2004.029.07.819330, ISSN 0377-8282, pages 673 - 676, XP008113000 [X] 1-3 * the whole document * * page 674, column l, paragraph 3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents